GREZF yields 3.18% · PFE yields 6.13%● Live data
📍 GREZF pulled ahead of the other in Year 1
Combined, GREZF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GREZF + PFE for your $10,000?
GREE, Inc., a technology company, engages in the online media business in Japan and internationally. It operates through Internet and Entertainment, and Investment and Incubation segments. The company provides GREE, a social networking services (SNS) platform, and social games and diverse content closely linked with SNS, offering a variety of entertainment related elements centered on user-to-user communication; and develops and operates app games for smartphones under the GREE, WFS, Pokelabo, and GREE Entertainment brands to app delivery platforms. It also operates REALITY, a metaverse virtual live streaming app; REALITY XR cloud, a cloud solution for virtual events that take place in any virtual space; and REALITY STUDIO, a virtual creative label that has produced a wide variety of talent, including KMNZ, VESPERBELL, and HACHI. In addition, the company operates aumo, a travel and lifestyle information services platform; LIMIA, an on-line magazine that features home and living lifestyle content; MINE, an on-line video magazine that features women's fashion, beauty, and lifestyle topics; and ARINE, an on-line magazine for young women with the latest content on topics. Further, it provides DX support for client business based on experiences and achievements; and produces, develops, and directs anime and manga IP content. Additionally, the company invests in startup companies operating mainly in the Internet and IT fields through venture capital funds or corporate venture capital. GREE, Inc. was founded in 2004 and is headquartered in Tokyo, Japan.
Full GREZF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.